COMPOSITIONS AND METHODS FOR EXOSOME TARGETED EXPRESSION
원문보기
IPC분류정보
국가/구분
United States(US) Patent
공개
국제특허분류(IPC7판)
C07K-014/005
A61K-038/16
A61K-039/39
A61K-045/06
C07K-014/16
G01N-033/566
A61K-009/127
C12P-021/02
G01N-033/543
C12N-015/00
A61K-038/00
A61K-039/00
출원번호
US-0660572
(2017-07-26)
공개번호
US-0369533
(2017-12-28)
발명자
/ 주소
Bond, Vincent C.
POWELL, Michael
HUANG, Ming Bo
ALI, Syed
출원인 / 주소
Bond, Vincent C.
인용정보
피인용 횟수 :
0인용 특허 :
0
초록▼
The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exoso
The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.
대표청구항▼
1-21. (canceled) 22. A Nef-fusion protein, produced by culturing cells that produce exosomes containing said Nef-fusion protein;isolating exosomes from said cells; andpurifying said Nef-fusion protein from isolated exosomes,wherein said Nef-fusion protein comprises a Nef-derived peptide fused to a p
1-21. (canceled) 22. A Nef-fusion protein, produced by culturing cells that produce exosomes containing said Nef-fusion protein;isolating exosomes from said cells; andpurifying said Nef-fusion protein from isolated exosomes,wherein said Nef-fusion protein comprises a Nef-derived peptide fused to a protein of interest and wherein said Nef-derived peptide comprises SEQ ID NO:3, 4, 5 or 6. 23. The Nef-fusion protein of claim 22, wherein said Nef-derived peptide comprises SEQ ID NO:3. 24. The Nef-fusion protein of claim 22, wherein said Nef-derived peptide comprises SEQ ID NO:4. 25. The Nef-fusion protein of claim 22, wherein said Nef-derived peptide comprises SEQ ID NO:5. 26. The Nef-fusion protein of claim 22, wherein said Nef-derived peptide comprises SEQ ID NO:6. 27. The Nef-fusion protein of claim 22, wherein said protein of interest is an immunogenic protein. 28. The Nef-fusion protein of claim 27, wherein said immunogenic protein comprises at least a portion of a tumor antigen. 29. The Nef-fusion protein of claim 22, further comprising one or more functional domains. 30. The Nef-fusion protein of claim 29, wherein the one or more functional domains are selected from the group consisting of affinity tags, protease cleavage sites, targeting domains, reporters and enzymes. 31. The Nef-fusion protein of claim 29, wherein the one or more functional domains comprise one or more affinity tags selected from the group consisting of glutathione S-transferase (GST), histidine tag, maltose binding protein (MBP), protein A, thioredoxin, ubiquitin, biotin, calmodulin binding peptide (CBP), streptavidin tag, FLAG octapeptide tag, hemaglutinin A (HA) tag, and myc tag. 32. The Nef-fusion protein of claim 29, wherein the one or more functional domains comprise one or more protease cleavage sites selected from the group consisting of cleavage sites sensitive to thrombin, furin, factor Xa, metalloproteases, enterokinases, or cathepsin. 33. The Nef-fusion protein of claim 29, wherein the one or more functional domains comprise one or more targeting domains selected from the group consisting of antibodies, antibody derivatives, peptide ligands, receptor ligands, receptor fragments and hormones. 34. A pharmaceutical composition, comprising: the Nef-fusion protein of claim 22; anda pharmaceutically acceptable carrier.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.